173 related articles for article (PubMed ID: 36259556)
1. Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis.
Zang S; Zhang X; Niu J; Das BB
Clin Transplant; 2023 Jan; 37(1):e14836. PubMed ID: 36259556
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus in renal transplant recipients from living donors with and without valganciclovir prophylaxis and with immunosuppression based on anti-thymocyte globulin or basiliximab.
Andrade-Sierra J; Heredia-Pimentel A; Rojas-Campos E; Ramírez Flores D; Cerrillos-Gutierrez JI; Miranda-Díaz AG; Evangelista-Carrillo LA; Martínez-Martínez P; Jalomo-Martínez B; Gonzalez-Espinoza E; Gómez-Navarro B; Medina-Pérez M; Nieves-Hernández JJ
Int J Infect Dis; 2021 Jun; 107():18-24. PubMed ID: 33862205
[TBL] [Abstract][Full Text] [Related]
3. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
Jewani PK; Pouch SM; Kissling KT
Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study.
Custodio LFP; Martins SBS; Viana LA; Cristelli MP; Requião-Moura L; Chow CYZ; Camargo SFDN; Nakamura MR; Foresto RD; Tedesco-Silva H; Medina-Pestana J
Pediatr Transplant; 2024 May; 28(3):e14713. PubMed ID: 38553819
[TBL] [Abstract][Full Text] [Related]
5. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
Luan FL; Samaniego M; Kommareddi M; Park JM; Ojo AO
Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
[TBL] [Abstract][Full Text] [Related]
6. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
[TBL] [Abstract][Full Text] [Related]
7. Antithymocyte globulin induction therapy and myocardial complement deposition in pediatric heart transplantation.
Ghaleb S; Wittekind SG; Martinez H; Kasten J; Gao Z; Hengehold T; Chin C
Pediatr Transplant; 2021 Sep; 25(6):e13998. PubMed ID: 33704881
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy.
Ko EJ; Yu JH; Yang CW; Chung BH
Korean J Intern Med; 2019 Mar; 34(2):375-382. PubMed ID: 29237252
[TBL] [Abstract][Full Text] [Related]
9. Impact of induction strategy change on first-year rejection in pediatric heart transplantation at a single center-From postoperative basiliximab to either postoperative anti-thymocyte globulin or preoperative basiliximab.
Sisson TM; Padilla LA; Hubbard M; Smith S; Pearce FB; Collins JL; Carlo WF
Clin Transplant; 2021 Jun; 35(6):e14314. PubMed ID: 33838071
[TBL] [Abstract][Full Text] [Related]
10. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database.
Butts RJ; Dipchand AI; Sutcliffe D; Bano M; Dimas V; Morrow R; Das B; Kirk R
Pediatr Transplant; 2018 Jun; 22(4):e13190. PubMed ID: 29878688
[TBL] [Abstract][Full Text] [Related]
12. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
Das BB; Prusty BK; Niu J; Sue PK
Pediatr Transplant; 2020 Dec; 24(8):e13750. PubMed ID: 32573886
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
Reusing JO; Feitosa EB; Agena F; Pierrotti LC; Azevedo LSF; Kotton CN; David-Neto E
Transpl Infect Dis; 2018 Oct; 20(5):e12929. PubMed ID: 29809309
[TBL] [Abstract][Full Text] [Related]
15. Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients.
Bonaros NE; Kocher A; Dunkler D; Grimm M; Zuckermann A; Ankersmit J; Ehrlich M; Wolner E; Laufer G
Transplantation; 2004 Mar; 77(6):890-7. PubMed ID: 15077033
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
[TBL] [Abstract][Full Text] [Related]
17. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab.
Pham C; Kuten SA; Knight RJ; Nguyen DT; Graviss EA; Gaber AO
Transpl Infect Dis; 2020 Jun; 22(3):e13257. PubMed ID: 32031729
[TBL] [Abstract][Full Text] [Related]
18. Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin.
Eriksson M; Jokinen JJ; Söderlund S; Hämmäinen P; Lommi J; Lemström K
Transpl Infect Dis; 2018 Jun; 20(3):e12868. PubMed ID: 29512249
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
20. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
